Neurotech International (NTI) has updated the ASX on the development of its proprietary formulation for the treatment of multiple sclerosis (MS).
NTI said results from an in-vitro study conducted in conjunction with Melbourne’s RMIT University showed its NTI/Dolce Strains suppressed the production of two key inflammatory neuro-markers involved in MS by 40% and 30% respectively. CBD alone had no significant effect.
NTI said it is committed to the development of a solid scientific portfolio to expand the application and use of the strains beyond autism. Further preclinical studies will inform the design of a Phase I/II clinical study in MS.
Company chairman Brian Leedman said: “There are a number of very powerful neuro-markers that are currently being used to assess disease onset and progression. To be able to suppress or regulate these markers may be very beneficial in overall disease management.”
